Matches in SemOpenAlex for { <https://semopenalex.org/work/W3012415317> ?p ?o ?g. }
- W3012415317 abstract "Abstract Background Depressive disorders are a leading cause of disability, but current behavioural and pharmacological therapies have a slow onset of response, typically taking several weeks before achieving efficacy. Prior studies using triplicate intravenous scopolamine infusions have been shown to reduce depressive symptomologies within days compared to saline placebo infusions. However, several parameters of scopolamine’s potential antidepressant effect remain unknown, such as its dose–response profile and its washout period. There is also the question as to whether the previously reported antidepressant responses were confounded by unblinding effects due to the lack of an active placebo control. Glycopyrronium bromide was selected as placebo for this trial given it has similar antimuscarinic properties to scopolamine hydrobromide but an inability to cross the blood–brain barrier, thereby hypothetically mimicking only the peripheral effects of scopolamine. Methods/Design A parallel group trial of single intravenous scopolamine infusions at three doses (4, 5, and 6 μg/kg) along with one glycopyrronium bromide 4 μg/kg group will be administered to 40 participants with major depressive disorder in a 1:1:1:2 ratio, respectively. The primary outcome measure will be the Montgomery–Åsberg Depression Rating Scale (MADRS) administered at baseline, 4 hours, 1 day, 3 days, 1 week, 2 weeks, 4 weeks, and 6 weeks post-infusion to determine antidepressant efficacy. As a secondary measure, the Quick Inventory of Depressive Symptomatology will be administered alongside the MADRS to further track potential antidepressant responses. Other secondary measures include electroencephalography, blood samples, and Bowdle visual acuity scales recorded at baseline, 5, 10, 15, 20, 30, 60, 120, and 240 min post-infusion to determine the pharmacokinetic-pharmacodynamic profile of scopolamine in depressed participants. Discussion This trial contributes to the literature surrounding the efficacy of scopolamine as an antidepressant. Determining the dose–response profile and washout period of scopolamine’s antidepressant effect will also provide important information for designing and conducting crossover trials. The use of an active placebo is important to reduce potentially confounding expectancy effects. Trial registration The trial was registered in the Australian New Zealand Clinical Trials Registry (registration number ACTRN12619000569101 ). Registered on 11 April 2019." @default.
- W3012415317 created "2020-03-23" @default.
- W3012415317 creator A5000583874 @default.
- W3012415317 creator A5016767488 @default.
- W3012415317 creator A5017285484 @default.
- W3012415317 creator A5025717731 @default.
- W3012415317 creator A5028907087 @default.
- W3012415317 creator A5056679294 @default.
- W3012415317 creator A5065919715 @default.
- W3012415317 creator A5076756708 @default.
- W3012415317 creator A5085832078 @default.
- W3012415317 date "2020-02-10" @default.
- W3012415317 modified "2023-09-29" @default.
- W3012415317 title "A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4–6 μg/kg) in patients with major depressive disorder" @default.
- W3012415317 cites W1152485255 @default.
- W3012415317 cites W1577969467 @default.
- W3012415317 cites W1953260479 @default.
- W3012415317 cites W1970133878 @default.
- W3012415317 cites W1980222994 @default.
- W3012415317 cites W1986641829 @default.
- W3012415317 cites W1993328356 @default.
- W3012415317 cites W1996072871 @default.
- W3012415317 cites W2000097034 @default.
- W3012415317 cites W2009122980 @default.
- W3012415317 cites W2024942342 @default.
- W3012415317 cites W2051925083 @default.
- W3012415317 cites W2057873186 @default.
- W3012415317 cites W2069138677 @default.
- W3012415317 cites W2074994806 @default.
- W3012415317 cites W2078788771 @default.
- W3012415317 cites W2085758661 @default.
- W3012415317 cites W2087484885 @default.
- W3012415317 cites W2090966916 @default.
- W3012415317 cites W2093627832 @default.
- W3012415317 cites W2095984639 @default.
- W3012415317 cites W2096525313 @default.
- W3012415317 cites W2097857685 @default.
- W3012415317 cites W2107026277 @default.
- W3012415317 cites W2113307128 @default.
- W3012415317 cites W2125999113 @default.
- W3012415317 cites W2131722356 @default.
- W3012415317 cites W2148580139 @default.
- W3012415317 cites W2151139045 @default.
- W3012415317 cites W2159570624 @default.
- W3012415317 cites W2167602908 @default.
- W3012415317 cites W2167761850 @default.
- W3012415317 cites W2184073179 @default.
- W3012415317 cites W2197394318 @default.
- W3012415317 cites W2414679562 @default.
- W3012415317 cites W2888904791 @default.
- W3012415317 cites W4236805817 @default.
- W3012415317 cites W4247665917 @default.
- W3012415317 cites W1572299467 @default.
- W3012415317 doi "https://doi.org/10.1186/s13063-020-4089-6" @default.
- W3012415317 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7011244" @default.
- W3012415317 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32041658" @default.
- W3012415317 hasPublicationYear "2020" @default.
- W3012415317 type Work @default.
- W3012415317 sameAs 3012415317 @default.
- W3012415317 citedByCount "1" @default.
- W3012415317 countsByYear W30124153172021 @default.
- W3012415317 crossrefType "journal-article" @default.
- W3012415317 hasAuthorship W3012415317A5000583874 @default.
- W3012415317 hasAuthorship W3012415317A5016767488 @default.
- W3012415317 hasAuthorship W3012415317A5017285484 @default.
- W3012415317 hasAuthorship W3012415317A5025717731 @default.
- W3012415317 hasAuthorship W3012415317A5028907087 @default.
- W3012415317 hasAuthorship W3012415317A5056679294 @default.
- W3012415317 hasAuthorship W3012415317A5065919715 @default.
- W3012415317 hasAuthorship W3012415317A5076756708 @default.
- W3012415317 hasAuthorship W3012415317A5085832078 @default.
- W3012415317 hasBestOaLocation W30124153171 @default.
- W3012415317 hasConcept C118552586 @default.
- W3012415317 hasConcept C126322002 @default.
- W3012415317 hasConcept C139719470 @default.
- W3012415317 hasConcept C142724271 @default.
- W3012415317 hasConcept C162324750 @default.
- W3012415317 hasConcept C169900460 @default.
- W3012415317 hasConcept C170493617 @default.
- W3012415317 hasConcept C204787440 @default.
- W3012415317 hasConcept C27081682 @default.
- W3012415317 hasConcept C2776867660 @default.
- W3012415317 hasConcept C2779177272 @default.
- W3012415317 hasConcept C2780051608 @default.
- W3012415317 hasConcept C2909050532 @default.
- W3012415317 hasConcept C33789571 @default.
- W3012415317 hasConcept C42219234 @default.
- W3012415317 hasConcept C558461103 @default.
- W3012415317 hasConcept C71924100 @default.
- W3012415317 hasConceptScore W3012415317C118552586 @default.
- W3012415317 hasConceptScore W3012415317C126322002 @default.
- W3012415317 hasConceptScore W3012415317C139719470 @default.
- W3012415317 hasConceptScore W3012415317C142724271 @default.
- W3012415317 hasConceptScore W3012415317C162324750 @default.
- W3012415317 hasConceptScore W3012415317C169900460 @default.
- W3012415317 hasConceptScore W3012415317C170493617 @default.
- W3012415317 hasConceptScore W3012415317C204787440 @default.
- W3012415317 hasConceptScore W3012415317C27081682 @default.
- W3012415317 hasConceptScore W3012415317C2776867660 @default.
- W3012415317 hasConceptScore W3012415317C2779177272 @default.